BD has over 70000 employees worldwide, with product lines including syringes, infusion systems, flow cytometers, microbiological testing platforms, and more. The company focuses on innovation and invests heavily in research and development every year, possessing over 15000 patented technologies. BD continues to expand its business footprint through strategic acquisitions such as Bard Healthcare and Confuchsin, and collaborates with organizations such as the World Health Organization and the Gates Foundation to promote the development of global public health. Its strict quality standards and sustainable business philosophy make it a trusted partner in the healthcare industry.

In 2023, BD's revenue will exceed $20 billion and significant progress will be made in the fields of intelligent medical devices and digital solutions. The company has recently launched a new generation of automated diagnostic systems and AI assisted medical technology, and has increased its layout in cutting-edge fields such as gene sequencing and cell therapy. BD continues to expand into emerging markets while fulfilling its ESG commitments, with plans to achieve carbon neutrality by 2030. In the future, BD will further consolidate its leadership position in the medical technology industry through technological innovation and global cooperation.